{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:44:42Z","timestamp":1793378682512,"version":"4.5.0"},"reference-count":25,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T00:00:00Z","timestamp":1487289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10 CA29511"],"award-info":[{"award-number":["U10 CA29511"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2017,6,15]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The identification of new therapies for high\u2010risk (HR) hepatoblastoma is challenging. Children's Oncology Group study AHEP0731 included a HR stratum to explore the efficacy of novel agents. Herein, the authors report the response rate to the combination of vincristine (V) and irinotecan (I) and the outcome of patients with high\u2010risk hepatoblastoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Patients with newly diagnosed metastatic hepatoblastoma or those with a serum \u03b1\u2010fetoprotein (AFP) level &lt;100 ng\/mL were eligible. Patients received 2 cycles of V at a dose of 1.5 mg\/m<jats:sup>2<\/jats:sup>\/day intravenously on days 1 and 8 and I at a dose of 50 mg\/m<jats:sup>2<\/jats:sup>\/day intravenously on days 1 to 5. Patients were defined as responders if they had either a 30% decrease in tumor burden according to Response Evaluation Criteria In Solid Tumors (RECIST) or a 90% (&gt;1 log<jats:sub>10<\/jats:sub>) decline in their AFP level. Responders were to receive 2 additional cycles of VI intermixed with 6 cycles of the combination of cisplatin, doxorubicin, 5\u2010fluorouracil, and vincristine (C5VD). Nonresponders were to receive 6 cycles of C5VD alone.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>A total of 32 patients with a median age at diagnosis of 26 months (range, 11\u2010159 months) were enrolled between September 2009 and February 2012. Fourteen of 30 evaluable patients were responders (RECIST and AFP in 6 patients, RECIST only in 3 patients, and AFP only in 5 patients). The median AFP decline after 2 cycles of VI for the entire group was 345,565 ng\/mL (85% of the initial AFP). The 3\u2010year event\u2010free and overall survival rates were 49% (95% confidence interval, 30%\u201065%) and 62% (95% confidence interval, 42%\u201077%), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The VI combination appears to have substantial activity against HR hepatoblastoma. The ultimate impact of this regimen in improving the outcomes of children with HR hepatoblastoma remains to be determined. <jats:bold><jats:italic>Cancer<\/jats:italic> 2017;123:2360\u20132367.<\/jats:bold> \u00a9 <jats:italic>2017 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.30591","type":"journal-article","created":{"date-parts":[[2017,2,17]],"date-time":"2017-02-17T10:05:04Z","timestamp":1487325904000},"page":"2360-2367","source":"Crossref","is-referenced-by-count":69,"title":["Upfront window vincristine\/irinotecan treatment of high\u2010risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee"],"prefix":"10.1002","volume":"123","author":[{"given":"Howard M.","family":"Katzenstein","sequence":"first","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology Monroe Carell Jr. Children's Hospital at Vanderbilt University, Nashville Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne L.","family":"Furman","sequence":"additional","affiliation":[{"name":"Department of Oncology St Jude Children's Research Hospital, Memphis Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio H.","family":"Malogolowkin","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology University of California at Davis Comprehensive Cancer Center, Sacramento California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Krailo","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine University of Southern California Keck School of Medicine, Los Angeles California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Beth","family":"McCarville","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging St Jude Children's Research Hospital, Memphis Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Towbin","sequence":"additional","affiliation":[{"name":"Department of Radiology and Medical Imaging Cincinnati Children's Hospital Medical Center, Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg M.","family":"Tiao","sequence":"additional","affiliation":[{"name":"Division of General and Thoracic Surgery Cincinnati Children's Hospital Medical Center, Cincinnati Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton J.","family":"Finegold","sequence":"additional","affiliation":[{"name":"Department of Pathology Baylor College of Medicine, Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarangarajan","family":"Ranganathan","sequence":"additional","affiliation":[{"name":"Department of Pathology Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Dunn","sequence":"additional","affiliation":[{"name":"Department of Surgery Nemours\/Alfred I. duPont Hospital for Children, Wilmington Delaware"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max R.","family":"Langham","sequence":"additional","affiliation":[{"name":"Division of Pediatric Surgery St Jude Children's Research Hospital, Memphis Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene D.","family":"McGahren","sequence":"additional","affiliation":[{"name":"Division of Pediatric Surgery University of Virginia Children's Hospital, Charlottesville Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Rodriguez\u2010Galindo","sequence":"additional","affiliation":[{"name":"Department of Global Pediatric Medicine St Jude Children's Research Hospital, Memphis Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecka L.","family":"Meyers","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery Primary Children's Medical Center, Salt Lake City Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000046"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00074-5"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22088"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.11.022"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950130405"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.12.2167"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.07.400"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1043805"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22544"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70272-9"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.6.1815"},{"key":"e_1_2_8_13_1","first-page":"813","article-title":"Pharmacokinetics of irinotecan and its metabolites SN\u201038 and APC in children with recurrent solid tumors after protracted low\u2010dose irinotecan","volume":"6","author":"Ma MK","year":"2000","journal-title":"Clin Cancer Res."},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-200212000-00014"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.10300"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22408"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.06.023"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.027"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1190"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.10.019"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.145"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118032985"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.6013"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.7107"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.30591","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.30591","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:47:41Z","timestamp":1760273261000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.30591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,17]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,6,15]]}},"alternative-id":["10.1002\/cncr.30591"],"URL":"https:\/\/doi.org\/10.1002\/cncr.30591","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,17]]}}}